<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832141</url>
  </required_header>
  <id_info>
    <org_study_id>Mobilization Thoracic Spine</org_study_id>
    <nct_id>NCT02832141</nct_id>
  </id_info>
  <brief_title>Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems</brief_title>
  <official_title>Effect of Thoracic Spine Mobilization on Skin-blood Flow, Erythema and Sympathetic Nervous Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bern University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bern University of Applied Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study aims to i) represents the feasibility of the study design and ii) to point
      out acute effects of thoracic spine mobilization on skin-blood flow, erythema and the
      sympathetic nervous system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: Adherence of recruited participants</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
    <description>Defined as the number of drop-outs and presence of participants which invited. Measurement unit: number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of the investigating procedure</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
    <description>Measured the burden of testing procedure. Measurement units = number and percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of the mobilization intervention from posterior-to-anterior on thoracic vertebrae</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
    <description>Measured adverse effects as pain and harm results to participants. Measurement units = number and percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of the mobilization intervention from anterior-to-posterior on thoracic vertebrae</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
    <description>Measured as adverse effects as pain and harm results to participants. Measurement units = number and percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of heart rate variability (HRV)</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>HRV is measured as the variations of the time interval between two consecutive cardiac beats registered by means Polar watch RS800 is used to measures (HRV). Measurement unit: High frequency-band (HF-Band) and Low frequency-band (LF-Band)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of systolic blood pressure value (mmHg)</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>Omron MIT Elite Plus is used for measuring systolic blood flow. iMeasurement units: mmHg (millimeter of mercury)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of diastolic blood pressure value (mmHg) changes</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>Omron MIT Elite Plus is used for measuring diastolic blood pressureMeasurement units: mmHg (millimeter of mercury)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of heartbeat frequency</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>Polar watch RS800 is used for measuring heartbeat frequency. Measurement units: beat per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of skin-blood flow variation</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>Laser doppler imaging is used for measuring microcirculatory changes. Measurement units: perfusion unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of erythema</measure>
    <time_frame>Change from baseline imediately after, 2, 4, 6, 8 and 10 minutes after the intervention</time_frame>
    <description>Tristimulus surface colorimetry is used for measuring erythema. Measurement units: Erythema index</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Erythema</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mobilization anterior</intervention_name>
    <description>Participant in prone position. Central thoracic mobilization from posterior-to-anterior.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Thoracic spine mobilization with anterior pressure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mobilization posterior</intervention_name>
    <description>Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Thoracic spine mobilization with posterior pressure</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy person between 20 and 30 years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20 - 30 years

          -  healthy persons

        Exclusion Criteria:

          -  current pain

          -  blood pressure medications

          -  osteoporosis

          -  cardiac or neurological symptoms

          -  pregnancy

          -  thromobosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Taeymans, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University of Applied Science, Departement Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bern University of Applied Science, Department Health</name>
      <address>
        <city>Bern</city>
        <zip>3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bern University of Applied Sciences</investigator_affiliation>
    <investigator_full_name>Slavko Rogan</investigator_full_name>
    <investigator_title>MSc, MA</investigator_title>
  </responsible_party>
  <keyword>Skin blood flow</keyword>
  <keyword>Skin redness</keyword>
  <keyword>Sympathetic nervous system</keyword>
  <keyword>Regional Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

